Science Industry Australia members recently gathered to discuss the implications of the federal government's budget on the science industry. [ + ]

AXT, a supplier of scientific equipment for industry and academia, has been appointed an official distributor for Selfrag in Australia and New Zealand. Selfrag designs and manufactures high-voltage pulse power fragmentation equipment for the geoscience, mining, recycling and solar industries. [ + ]

AusBiotech has made a submission to the Board of Taxation, which is conducting a review to identify features in the tax system that are hindering or preventing small businesses from reaching their commercial goals. [ + ]

Sydney life science and ICT business incubator ATP Innovations has won the Incubator of the Year Award at the NBIA's 2014 International Conference. [ + ]

QRxPharma (ASX:QRX) has, as expected, received a third Complete Response Letter from the US FDA covering a New Drug Application for pain drug Moxduo. [ + ]

Qiagen has announced that its therascreen KRAS RGQ PCR Kit has received US FDA approval to guide the treatment of metastatic colorectal cancer patients with Amgen's Vectibix (panitumumab). [ + ]

ResMed (ASX:RMD) has presented research into a new algorithm for providing APAP therapy that has been customised to reflect the distinct symptoms of female sleep apnoea patients. [ + ]

The Australian Academy of Technological Sciences and Engineering (ATSE) Clunies Ross Awards Dinner was held this week at the Perth Convention Centre. The event celebrates Australia's heroes in science and technology. [ + ]

Positive results for Rhinomed’s sport and respiratory technology, Turbine, will be followed later this year with the release of its first products targeting snoring and sleep quality.     [ + ]

Scientists from ANSTO and Thailand’s Naresuan University have helped to make carbon dating a more accurate chronological tool. [ + ]

Clinuvel (ASX:CUV) has in one week been granted orphan status for its Scenesse drug in Hailey-Hailey disease in both the US and the EU. [ + ]

DB Pharm Korea has signed a deal giving it exclusive rights to distribute Immuron's (ASX:IMC) travellers' diarrhoea treatment Travelan in South Korea. [ + ]

Commercialisation Australia (CA) is now closed for new applications, following the announcement in last week's federal Budget that it will cease from 1 January 2015 and the funds will be rolled into the new Entrepreneurs' Infrastructure Program (EIP). [ + ]

Immune System Therapeutics (IST) has announced plans to place up to $5m in new shares, to raise funds for a phase IIb multiple myeloma trial and an ASX listing in the third quarter. [ + ]

Entries are open for this year's The Australian Innovation Challenge awards, honouring excellence in fields from minerals and energy to ICT and community services. [ + ]